Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest Butler

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
BMJ Open Sport & Exercise Medicine|February 25, 2026
Clinician-led, single-blind, randomised controlled trial evaluating the efficacy of a high-intensity resistance and impact training intervention for improving health-related quality of life in people with multiple sclerosis: protocol for STRONG-MSLisa Grech, Belinda Beck, David Scott, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Genome Research|February 27, 2025
A prospective trial comparing programmable targeted long-read sequencing and short-read genome sequencing for genetic diagnosis of cerebellar ataxiaHaloom Rafehi, Liam G Fearnley, Justin Read, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2Jessica Shipley, James Beharry, Wei Yeh, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1Jessica Shipley, James Beharry, Wei Yeh, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
BMJ Open Sport & Exercise Medicine|February 25, 2026
Clinician-led, single-blind, randomised controlled trial evaluating the efficacy of a high-intensity resistance and impact training intervention for improving health-related quality of life in people with multiple sclerosis: protocol for STRONG-MSLisa Grech, Belinda Beck, David Scott, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Genome Research|February 27, 2025
A prospective trial comparing programmable targeted long-read sequencing and short-read genome sequencing for genetic diagnosis of cerebellar ataxiaHaloom Rafehi, Liam G Fearnley, Justin Read, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2Jessica Shipley, James Beharry, Wei Yeh, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1Jessica Shipley, James Beharry, Wei Yeh, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.
Pageof 5